CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 18 enrolled
Drug / intervention
Bupropion XL +1 moredrug
Likely dose
Bupropion XL 150 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04352101
NCT04352101Phase 4Completed
CompareCT.gov

Effects of Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits in Patients With Major Depression and Increased Inflammation and Anhedonia

Emory University·interventional·Posted Apr 20, 2020·Updated Dec 29, 2023

In Brief

A Phase 4 clinical trial evaluating Bupropion XL and Escitalopram for Major Depression. Completed, enrolled 18 participants across 1 site.

Detailed Summary

This study is designed to determine whether bupropion (vs escitalopram) increases functional connectivity (FC) within reward-related neurocircuits and decreases motivational deficits in depressed patients with increased inflammation and anhedonia. Participants will be randomized to take bupropion extended release (XL) or escitalopram for 8 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depression
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedApr 20, 2020
Enrollment StartSep 23, 2020
Primary CompletionJul 25, 2022
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 6.2 years ago

Interventions

Bupropion XLdrug

Participants will take 150 milligrams per day (mg/d) of bupropion XL for two weeks, then the dose will be increased to 300mg/d, as tolerated, for the remaining 6 weeks of the study.

Escitalopramdrug

Participants will take 10mg/d of escitalopram for two weeks, then the dose will be increased to 20mg/d, as tolerated, for the remaining 6 weeks of the study.